Breast cancer study uncovers how macrophages may contribute to a therapeutic weak spot

Breast cancer, the second most common cancer in the United States, can result from a number of cellular misregulations, such as deficiencies in the DNA-repairing breast cancer gene, BRCA. Typically, BRCA-associated breast cancer is treated with poly ADP ribose polymerase (PARP) inhibitors and, recently, clinical trials have investigated pairing PARP inhibitor therapy with immunotherapy. Based…

Invirsa obtains license from Nationwide Children’s Hospital to fight respiratory diseases

Columbus, OH – Dec. 18, 2020 – Invirsa, a Columbus-based pharmaceutical company, today announced execution of a license agreement with the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital as Invirsa seeks to broaden its treatment platform to address respiratory diseases. The announcement coincides with Invirsa’s securing a $16.9 million contract from the government…